Filing Flows › Fate Therapeutics (FATE) › Q2 2025
Fate Therapeutics (FATE) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 12, 2025
Fate Therapeutics (FATE) reported revenue of $1.9M for the second quarter 2025 (Q2 2025), -72% from a year earlier and +17% from the quarter before.
Fate Therapeutics, Q2 2025: revenue $1.9M (-72% year over year), net loss $34.1M, operating cash flow −$24.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.9M | +17% | -72% |
| Operating profit | −$37.0M | — | — |
| Net earnings | −$34.1M | — | — |
| Operating cash flow | −$24.6M | — | — |
What changed
Revenue was $1.9M in Q2 2025, down 72% year over year and up 17% from the previous quarter.
Operating costs exceeded revenue by $37.0M, an operating margin of -1938.5%. Total costs fell 25% while revenue fell 72%. The quarter ended with a net loss of $34.1M, narrower than the previous quarter's $37.6M loss.
Operating cash flow was −$24.6M. Non-cash charges added back $3.3M of depreciation and amortization and $7.2M of share-based compensation. Capital expenditures of $1.4M exceeded it, leaving free cash flow of −$25.9M.
Questions
What was Fate Therapeutics' revenue in the second quarter 2025?
Fate Therapeutics (FATE) reported revenue of $1.9M for the second quarter 2025 (Q2 2025), -72% from a year earlier and +17% from the quarter before.
Source: Fate Therapeutics 10-Q on SEC EDGAR.